Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239328 | 0.92 | HPGD (0.46) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL12239286 | 0.90 | MGLL (0.46) | MEN1KMT2AMGLLHSD11B1POLB | |
| SCHEMBL12239278 | 0.89 | HTT (0.45) | MEN1KMT2ACYP2C19POLBALDH1A1 | |
| SCHEMBL12239287 | 0.88 | TSHR (0.48) | HSD11B1 | |
| SCHEMBL12239284 | 0.86 | KMT2A (0.50) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL12239279 | 0.85 | CHRM2 (0.42) | MEN1KMT2ACYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL12239283 | 0.84 | SMN1; SMN2 (0.46) | MEN1KMT2AMGLLHSD11B1POLB | |
| SCHEMBL12239251 | 0.84 | HTT (0.41) | MEN1KMT2ACYP2C19POLBALDH1A1 | |
| SCHEMBL12239281 | 0.84 | HSD11B1 (0.46) | MEN1KMT2AHSD11B1POLBALDH1A1 | |
| SCHEMBL12239280 | 0.83 | CYP2C9 (0.51) | MEN1KMT2AMGLLCYP2C19HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096560-B2 | 5-heterocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enones as herbicides | SYNGENTA LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096560-B2 | 5-heterocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enones as herbicides | SYNGENTA LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-20130053385-A1 | METHOD OF COMBATING AND CONTROLLING PESTS | SYNGENTA LIMITED (GB) | 2013-02-28 | — | — | US | disclosed |
| US-20130053385-A1 | METHOD OF COMBATING AND CONTROLLING PESTS | SYNGENTA LIMITED (GB) | 2013-02-28 | — | — | US | disclosed |
| US-20110263428-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263428-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011073060-A2 | METHOD OF COMBATING AND CONTROLLING PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010000773-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | SYNGENTA LIMITED (GB) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263428-A1 | 5-HETEROCYCLYLALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-ENONES AS HERBICIDES | DDT, CYP1B1, AHR | MEN1 3917/4885KMT2A 745/4885MGLL 1870/4885 |
| US-20130053385-A1 | METHOD OF COMBATING AND CONTROLLING PESTS | ACHE, ALG1, KEAP1 | MEN1 2172/4885KMT2A 2336/4885MGLL 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.